<a href="https://laohu8.com/S/OCGN">Ocugen</a> Inc. Enters Partnership with Korean Pharma Leader for Exclusive Licensing of OCU400 Gene Therapy
Ocugen Inc., a leader in gene therapies for blindness diseases, has entered a partnership with a prominent pharmaceutical and healthcare company in Korea. This collaboration grants the Korean company exclusive rights to Ocugen's OCU400, an innovative modifier gene therapy for retinitis pigmentosa. The agreement includes significant financial terms, with Ocugen set to receive up to $11 million from upfront and development milestone payments. Furthermore, Ocugen will earn sales milestones and a 25% royalty on net sales. The company will also handle the commercial supply of OCU400. This partnership aims to leverage the Korean company's expertise to treat thousands of patients with retinitis pigmentosa in Korea, aligning with Ocugen's strategy to maximize patient reach and shareholder returns.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463821-en) on June 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。